Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
Schmidt  E, Zillikens  D.  Pemphigoid diseases.  Lancet. 2013;381(9863):320-332.PubMedGoogle ScholarCrossref
2.
Zillikens  D, Rose  PA, Balding  SD,  et al.  Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies.  J Invest Dermatol. 1997;109(4):573-579.PubMedGoogle ScholarCrossref
3.
Schmidt  E, Reimer  S, Kruse  N,  et al.  Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes.  J Invest Dermatol. 2000;115(5):842-848.PubMedGoogle ScholarCrossref
4.
Liu  Z, Diaz  LA, Troy  JL,  et al.  A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.  J Clin Invest. 1993;92(5):2480-2488.PubMedGoogle ScholarCrossref
5.
Nishie  W, Sawamura  D, Goto  M,  et al.  Humanization of autoantigen.  Nat Med. 2007;13(3):378-383.PubMedGoogle ScholarCrossref
6.
Hirose  M, Recke  A, Beckmann  T,  et al.  Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice.  J Immunol. 2011;187(3):1176-1183.PubMedGoogle ScholarCrossref
7.
Schulze  FS, Beckmann  T, Nimmerjahn  F,  et al.  Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid.  Am J Pathol. 2014;184(8):2185-2196.PubMedGoogle ScholarCrossref
8.
Schmidt  E, Obe  K, Bröcker  EB, Zillikens  D.  Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.  Arch Dermatol. 2000;136(2):174-178.PubMedGoogle ScholarCrossref
9.
Amo  Y, Ohkawa  T, Tatsuta  M,  et al.  Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid.  J Dermatol Sci. 2001;26(1):14-18.PubMedGoogle ScholarCrossref
10.
Christophoridis  S, Büdinger  L, Borradori  L, Hunziker  T, Merk  HF, Hertl  M.  IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.  Br J Dermatol. 2000;143(2):349-355.PubMedGoogle ScholarCrossref
11.
Kromminga  A, Scheckenbach  C, Georgi  M,  et al.  Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.  J Autoimmun. 2000;15(3):293-300.PubMedGoogle ScholarCrossref
12.
Dresow  SK, Sitaru  C, Recke  A, Oostingh  GJ, Zillikens  D, Gibbs  BF.  IgE autoantibodies against the intracellular domain of BP180.  Br J Dermatol. 2009;160(2):429-432.PubMedGoogle ScholarCrossref
13.
Döpp  R, Schmidt  E, Chimanovitch  I, Leverkus  M, Bröcker  EB, Zillikens  D.  IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.  J Am Acad Dermatol. 2000;42(4):577-583.PubMedGoogle Scholar
14.
Messingham  KA, Noe  MH, Chapman  MA, Giudice  GJ, Fairley  JA.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.  J Immunol Methods. 2009;346(1-2):18-25.PubMedGoogle ScholarCrossref
15.
Ishiura  N, Fujimoto  M, Watanabe  R,  et al.  Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.  J Dermatol Sci. 2008;49(2):153-161.PubMedGoogle ScholarCrossref
16.
Pomponi  D, Di Zenzo  G, Zennaro  D,  et al.  Detection of IgG and IgE reactivity to BP180 using the ISAC® microarray system.  Br J Dermatol. 2013;168(6):1205-1214.PubMedGoogle ScholarCrossref
17.
Liu  B, Zuo  YG, Zhou  XP,  et al.  Establishment of enzyme-linked immunosorbent assay in the detection of BP180NC16A-specific IgE and its significance in bullous pemphigoid [in Chinese].  Zhonghua Yi Xue Za Zhi. 2013;93(28):2244-2247.PubMedGoogle Scholar
18.
Iwata  Y, Komura  K, Kodera  M,  et al.  Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.  Arch Dermatol. 2008;144(1):41-48.PubMedGoogle ScholarCrossref
19.
Provost  TT, Tomasi  TB  Jr.  Immunopathology of bullous pemphigoid: basement membrane deposition of IgE, alternate pathway components and fibrin.  Clin Exp Immunol. 1974;18(2):193-200.PubMedGoogle Scholar
20.
Yayli  S, Pelivani  N, Beltraminelli  H,  et al.  Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis.  Br J Dermatol. 2011;165(5):1133-1137.PubMedGoogle ScholarCrossref
21.
Messingham  KN, Srikantha  R, DeGueme  AM, Fairley  JA.  FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid.  J Immunol. 2011;187(1):553-560.PubMedGoogle ScholarCrossref
22.
Zone  JJ, Taylor  T, Hull  C, Schmidt  L, Meyer  L.  IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice.  J Invest Dermatol. 2007;127(5):1167-1174.PubMedGoogle ScholarCrossref
23.
Fairley  JA, Burnett  CT, Fu  C-L, Larson  DL, Fleming  MG, Giudice  GJ.  A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice.  J Invest Dermatol. 2007;127(11):2605-2611.PubMedGoogle ScholarCrossref
24.
della Torre  R, Combescure  C, Cortés  B,  et al.  Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort.  Br J Dermatol. 2012;167(5):1111-1117.PubMedGoogle ScholarCrossref
25.
Kippes  W, Schmidt  E, Roth  A, Rzany  B, Bröcker  EB, Zillikens  D.  Immunopathologic changes in 115 patients with bullous pemphigoid [in German].  Hautarzt. 1999;50(12):866-872.PubMedGoogle ScholarCrossref
26.
van Beek  N, Schulze  FS, Zillikens  D, Schmidt  E.  IgE-mediated mechanisms in autoimmune bullous diseases.  Expert Rev Clin Immunol. 2016;12(3):267-277.PubMedGoogle ScholarCrossref
27.
Dvorak  AM, Mihm  MC  Jr, Osage  JE, Kwan  TH, Austen  KF, Wintroub  BU.  Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient.  J Invest Dermatol. 1982;78(2):91-101.PubMedGoogle ScholarCrossref
28.
Yu  KK, Crew  AB, Messingham  KAN, Fairley  JA, Woodley  DT.  Omalizumab therapy for bullous pemphigoid.  J Am Acad Dermatol. 2014;71(3):468-474.PubMedGoogle ScholarCrossref
29.
Fairley  JA, Baum  CL, Brandt  DS, Messingham  KAN.  Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.  J Allergy Clin Immunol. 2009;123(3):704-705.PubMedGoogle ScholarCrossref
30.
London  VA, Kim  GH, Fairley  JA, Woodley  DT.  Successful treatment of bullous pemphigoid with omalizumab.  Arch Dermatol. 2012;148(11):1241-1243.PubMedGoogle ScholarCrossref
31.
World Medical Association.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.  JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053PubMedGoogle ScholarCrossref
32.
van Beek  N, Dohse  A, Riechert  F,  et al.  Serum autoantibodies against the dermal-epidermal junction in patients with chronic pruritic disorders, elderly individuals and blood donors prospectively recruited.  Br J Dermatol. 2014;170(4):943-947.PubMedGoogle ScholarCrossref
33.
Murrell  DF, Daniel  BS, Joly  P,  et al.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.  J Am Acad Dermatol. 2012;66(3):479-485.PubMedGoogle ScholarCrossref
34.
Kalowska  M, Ciepiela  O, Kowalewski  C, Demkow  U, Schwartz  RA, Wozniak  K.  Enzyme-linked immunoassay index for Anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid.  Acta Derm Venereol. 2016;96(2):191-196.PubMedGoogle ScholarCrossref
35.
Delaporte  E, Dubost-Brama  A, Ghohestani  R,  et al.  IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid.  J Immunol. 1996;157(8):3642-3647.PubMedGoogle Scholar
36.
Kamiya  K, Aoyama  Y, Noda  K,  et al.  Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.  J Dermatol Sci. 2015;78(1):77-79.PubMedGoogle ScholarCrossref
37.
Kleine-Tebbe  J, Jakob  T.  Molecular allergy diagnostics using IgE singleplex determinations: methodological and practical considerations for use in clinical routine: part 18 of the Series Molecular Allergology.  Allergo J Int. 2015;24:185-197.PubMedGoogle ScholarCrossref
38.
Johansson  SGO, Nopp  A, Oman  H,  et al.  The size of the disease relevant IgE antibody fraction in relation to “total-IgE” predicts the efficacy of anti-IgE (Xolair) treatment.  Allergy. 2009;64(10):1472-1477.PubMedGoogle ScholarCrossref
39.
Hamilton  RG, MacGlashan  DW  Jr, Saini  SS.  IgE antibody-specific activity in human allergic disease.  Immunol Res. 2010;47(1-3):273-284.PubMedGoogle ScholarCrossref
40.
Feliciani  C, Joly  P, Jonkman  MF,  et al.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology.  Br J Dermatol. 2015;172(4):867-877.PubMedGoogle ScholarCrossref
41.
Schmidt  E, Goebeler  M, Hertl  M,  et al.  S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid.  J Dtsch Dermatol Ges. 2015;13(7):713-727.PubMedGoogle Scholar
42.
Messingham  KN, Holahan  HM, Frydman  AS, Fullenkamp  C, Srikantha  R, Fairley  JA.  Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid.  PLoS One. 2014;9(9):e107725.PubMedGoogle ScholarCrossref
43.
Weidinger  S, Novak  N.  Atopic dermatitis.  Lancet. 2016;387(10023):1109-1122.PubMedGoogle ScholarCrossref
Original Investigation
January 2017

Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity

Author Affiliations
  • 1Department of Dermatology, University of Lübeck, Lübeck, Germany
  • 2Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
JAMA Dermatol. 2017;153(1):30-38. doi:10.1001/jamadermatol.2016.3357
Key Points

Question  In bullous pemphigoid (BP), are serum levels of IgE autoantibodies against BP180 NC16A correlated with the disease activity or associated with the urticarial phenotype?

Findings  In this noninterventional study, anti-BP180 NC16A serum IgE was found in 47 of 117 (40.2%) BP cases, which paralleled disease activity but showed no association with urticarial or erythematous lesions. In contrast, the presence of anti-BP180 NC16A IgG was associated with the presence of erosions and blisters.

Meaning  Anti-BP180 NC16A IgE appears to be of pathogenic significance, although its exact pathogenic role remains to be elucidated.

Abstract

Importance  Bullous pemphigoid (BP) is by far the most frequent autoimmune blistering disease. The presence of IgE autoantibodies against the transmembrane protein BP antigen 2 (BP180, type XVII collagen) has previously been reported in 22% to 100% of BP serum samples, and the pathogenic relevance of anti-BP180 IgE has been suggested in various experimental models and by the successful use of omalizumab in individual patients with BP.

Objectives  To determine the rate of anti-BP180–reactive IgE in BP, to evaluate the diagnostic relevance of anti-BP180 IgE in BP, and to correlate anti-BP180 IgE with disease activity and the clinical phenotype of patients with BP.

Design, Setting, and Participants  This case-control cohort study examined 3 groups of patients with BP. Sixty-five patients with BP underwent an enzyme-linked immunosorbent assay for IgE antibodies against the 16th noncollagenous domain of BP180 (NC16A); 52 consecutive patients with BP underwent clinical evaluation with the Bullous Pemphigoid Disease Activity Index (BPDAI); and 36 patients with BP without anti-BP180 NC16A IgG reactivity underwent evaluation of the diagnostic importance of serum anti-BP180 IgE. In addition, 49 age-matched control individuals with noninflammatory dermatoses, 127 controls undergoing allergy testing for IgE levels, and 30 controls with pemphigus vulgaris or pemphigus foliaceus were included for comparison. Patients were seen at a university clinic from January 1, 2008, to July 31, 2014.

Main Outcomes and Measures  Serum anti-BP180 NC16A IgE and IgG levels and BPDAI scores.

Results  Of 117 patients with BP (69 women and 48 men), anti-BP180 NC16A serum IgE was detected in 47 (40.2%) and correlated with disease activity as measured by total BPDAI (r = 0.918; P = .06). An intraindividual correlation of anti-BP180 NC16A serum levels with the total BPDAI was observed during the course of the disease in 10 randomly selected patients with BP (r = 0.983; P = .003). Although no association of circulating BP180 NC16A IgE antibodies with urticarial or erythematous lesions was observed (r = 0.481; P = .31), the presence of IgG anti-BP180 NC16A antibodies was associated with the occurrence of erosions and blisters (r = 0.985; P = .006) but not urticarial and erythematous lesions (r = 0.632; P = .23). Assaying for anti-BP180 IgE increased the diagnostic sensitivity by only 2.2% (1 of 46 serum samples) when combined with the IgG anti-BP180 enzyme-linked immunosorbent assay.

Conclusions and Relevance  Although detection of serum anti-BP180 IgE is not of diagnostic importance, it may be relevant for therapeutic decisions (eg, the use of anti-IgE treatment). The correlation of serum anti-BP180 NC16A IgE levels with disease activity in patients with BP supports the notion that anti-BP180 IgE is of pathogenic relevance. Our observation that IgG anti-BP180 antibodies are related to the occurrence of blisters and erosions may encourage further studies on the association of fine autoantibody reactivities with clinical features of BP.

×